A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2015
Price : $35 *
At a glance
- Drugs Sucroferric oxyhydroxide (Primary)
- Indications Hyperphosphataemia
- Focus Registrational; Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 30 Sep 2015 According to a Galenica Group media release, the New Drug Application (NDA) for sucroferric oxyhydroxide in the treatment of hyperphosphatemia has been approved by the Ministry of Health, Labour and Welfare in Japan.
- 12 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jun 2014 New trial record